MedTrace Logo

A Study of NBL-012 in Healthy Chinese Subjects

NCT05259189 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-07-20

No results posted yet for this study

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the safety, tolerability and pharmacokinetics (PK) of NBL-012 as single ascending doses (SAD) administered subcutaneously to healthy Chinese subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

NBL-012 Injection

a single subcutaneous injection

DRUG

Placebo

a single subcutaneous injection

Sponsors & Collaborators

  • NovaRock Biotherapeutics, Ltd

    lead INDUSTRY

Principal Investigators

  • Liyan Miu, MD PhD · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-05-23
Completion
2022-05-23
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259189 on ClinicalTrials.gov